Diabetes Metab J.  2022 Jan;46(1):160-161. 10.4093/dmj.2021.0309.

Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study (Diabetes Metab J 2021;45:675-83)

• Oh TJ

• KMID: 2525136
• DOI: http://doi.org/10.4093/dmj.2021.0309

Reference

1. Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018; 20:488–96.

2. Jung CH, Son JW, Kang S, Kim WJ, Kim HS, Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021; 45:1–10.

3. Holden SE, Gale EA, Jenkins-Jones S, Currie CJ. How many people inject insulin?: UK estimates from 1991 to 2010. Diabetes Obes Metab. 2014; 16:553–9.

4. Moon JS, Suh S, Kim SS, Jin HY, Kim JM, Jang MH, et al. Efficacy and safety of treatment with quadruple oral hypoglycemic agents in uncontrolled type 2 diabetes mellitus: a multi-center, retrospective, observational study. Diabetes Metab J. 2021; 45:675–83.

5. Cho YK, Lee J, Kim HS, Park JY, Jung CH, Lee WJ. Clinical efficacy of quadruple oral therapy for type 2 diabetes in realworld practice: a retrospective observational study. Diabetes Ther. 2020; 11:2029–39.

6. Karter AJ, Moffet HH, Liu JY, Lipska KJ. Surveillance of hypoglycemia: limitations of emergency department and hospital utilization data. JAMA Intern Med. 2018; 178:987–8.